ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2206

Adolescents with Systemic Lupus Erythematosus at Highest Risk of Adverse Pregnancy Outcomes

Catherine Deffendall1, Sarah Green2, Ashley Suh2, Bryan Han2 and April Barnado2, 1Vanderbilt University, Nashville, TN, 2Vanderbilt University Medical Center, Nashville, TN

Meeting: ACR Convergence 2025

Keywords: Pediatric rheumatology, pregnancy, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2195–2226) Reproductive Issues in Rheumatic Disorders Posters

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Few studies exist that examine pregnancy outcomes in adolescents with SLE. To our knowledge, there have been no studies comparing SLE adolescent pregnancies to both adolescent control and adult SLE pregnancies. Using a de-identified electronic health record (EHR), we compared rates of pregnancy outcomes in adolescents ≤ 21 years with and without SLE to older individuals with SLE.

Methods: We identified SLE pregnancies in a de-identified EHR with >3.8 million individuals using a validated algorithm of ≥ 4 SLE ICD billing codes and ≥ 1 pregnancy or delivery codes. On chart review, we confirmed SLE diagnosis by a rheumatologist and excluded deliveries occurring before SLE diagnosis. Pregnancies at a maternal age ≤ 21 years were counted as adolescent pregnancies and pregnancies at a maternal age ≥ 22 years were considered adult pregnancies. We identified control individuals as those without ICD codes for autoimmune diseases and ≥ 1 pregnancy or delivery codes. Maternal outcomes included gestational diabetes, preeclampsia, postpartum hemorrhage, peripartum infection. Fetal outcomes were pregnancy loss, which included elective termination, spontaneous abortion, and stillbirth. Other fetal outcomes were premature birth, defined as delivery < 37 weeks, and small for gestational age, defined as birth weight < 10th percentile for gestational age. Covariates were assessed on chart review. Using Chi-square and Kruskal-Wallis tests, we compared demographics and pregnancy outcomes. Since individuals could contribute multiple pregnancies and parity can impact outcomes, we performed mixed effects models to estimate the association of pregnancy loss, preterm birth, and preeclampsia with age at delivery, race, and SLE case status.

Results: We identified 32 pregnancies to 27 individuals with SLE ≤ 21 years, 146 pregnancies to 90 adolescent control individuals without SLE, and 266 pregnancies to 182 individuals with SLE aged ≥ 22 years (Table 1). Adults with SLE were more likely to be White than adolescents with or without SLE (p < 0.001), and SLE pregnancies were more likely to be complicated by hypertension compared to controls (p < 0.001). Compared to adolescent control pregnancies, adolescent SLE pregnancies were more likely to experience preeclampsia (p < 0.001), postpartum hemorrhage (p = 0.001), and preterm delivery (p = 0.001). Among SLE pregnancies, SLE adolescents were more likely to have antiphospholipid antibody syndrome (p = 0.01) and nephritis (p = 0.001) compared to SLE adults. Adolescents with SLE were more likely to have pregnancy loss than adults with SLE (p = 0.02). In mixed effects models, SLE cases were more likely to experience preterm delivery (OR = 9.11, 95% CI 4.10-20.22) and preeclampsia (OR = 5.55, 95% CI 2.38 – 12.92) after adjusting age at delivery and race.

Conclusion: Adolescent SLE pregnancies were more likely to have preterm birth, preeclampsia, and post-partum hemorrhage than control adolescents and more likely than adults with SLE to have pregnancy loss. Adolescents with SLE represent a high-risk pregnancy group that needs close monitoring.

Supporting image 1Figure 1. Flowchart of study individuals. (A) SLE pregnancies were selected from the de-identified electronic health record (EHR) using four or more SLE ICD-9 or ICD-10-CM

codes while also requiring one or more ICD-9 or ICD-10-CM pregnancy or delivery-related codes. We then performed chart review to confirm SLE diagnosis by a rheumatologist and ensure pregnancy occurred after SLE diagnosis. After applying age criteria, we identified adolescent SLE pregnancies and adult SLE pregnancies. (B) Control pregnancies were selected from the same de-identified EHR as the SLE pregnancies. Controls were required to have the same pregnancy and delivery-related codes used for SLE deliveries and to not have ICD-9 or ICD-10-CM codes for autoimmune diseases. We then performed chart review on a random set of 250 controls to ensure no autoimmune diseases. After applying age criteria, we identified adolescents without SLE.

Supporting image 2

Supporting image 3


Disclosures: C. Deffendall: None; S. Green: None; A. Suh: None; B. Han: None; A. Barnado: None.

To cite this abstract in AMA style:

Deffendall C, Green S, Suh A, Han B, Barnado A. Adolescents with Systemic Lupus Erythematosus at Highest Risk of Adverse Pregnancy Outcomes [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/adolescents-with-systemic-lupus-erythematosus-at-highest-risk-of-adverse-pregnancy-outcomes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adolescents-with-systemic-lupus-erythematosus-at-highest-risk-of-adverse-pregnancy-outcomes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology